PPARG and early-onset autosomal dominant Alzheimer disease: These studies have played a theoretical role in supporting our discovery that EA can also improve CP symptoms by activating the PPAR pathway, especially PPAR‐γ, indicating its potential for anti‐inflammatory and neuroprotective effects akin to those observed in Alzheimer's disease and other neurological conditions.